Get informed when a big investor buys or sells
+ FollowNovember 11, 2026 - AI Summary
Loading insider trades…
Loading congress trades…
| Market cap | $4.37 Billion |
|---|---|
| Enterprise Value | $9.36 Billion |
| Annual dividend | $0.20 |
| Dividend yield | 1.94% |
| Earnings per Share | $0 |
| Beta | 0.61 |
| Outstanding Shares | 198,700,000 |
| P/E Ratio | 14.54 |
|---|---|
| PEG | 96.41 |
| Price to Sales | 0.17 |
| Price to Book Ratio | 0.15 |
| Enterprise Value to Revenue | 0.36 |
| Enterprise Value to EBIT | 1.4 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.93 |
| Debt to Equity | 0.31 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...